Increasing women's choices in medical abortion: A study of misoprostol 400 μg swallowed immediately or held sublingually following 200 mg mifepristone

European Journal of Contraception and Reproductive Health Care

Volumn 14, Issue 3, 2009, Pages 169-175

  Akn, Aye ^a   Dabash, Rasha ^d   Dilbaz, Berna ^c   Aktn, Hale ^c   Dursun, Polat ^a   Kran, Sibel ^b   Aksan, Gldeniz ^a   Doan, Bahar ^a   Winikoff, Beverly ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b MOH Etlik Hospital   (Turkey)

^c Zekai Tahir Burak Mother Health Training and Research Hospital   (Turkey)

^d GYNUITY HEALTH PROJECTS   (United States)

Author keywords

Medical abortion; Mifepristone; Oral misoprostol; Sublingual misoprostol; Turkey

Indexed keywords

MIFEPRISTONE; MISOPROSTOL; ABORTIVE AGENT;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CHILL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ABORTION; MEDICAL DECISION MAKING; MENSTRUAL CYCLE; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; TURKEY (REPUBLIC); VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; FIRST TRIMESTER PREGNANCY; FOLLOW UP; INDUCED ABORTION; METHODOLOGY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PREGNANCY; SUBLINGUAL DRUG ADMINISTRATION;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; PREGNANCY TRIMESTER, FIRST; TURKEY; YOUNG ADULT;

EID: 70349777692     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180902916020     Document Type: Article

References (23)

1. United Nations Secretariat, Population Division of the Department of Economic and Social Affairs, Population Policy Data Bank.
2. Turkish Republic Ministry of Health, Mother and Child Health and Family Planning Directorate, State Planning Organisation and European Union. Turkish Demographic and Health Survey 2003. Hacettepe University Institute of Population Studies, Ankara, 2004.
3. Akýn A, Enunlu T. Induced abortions in Turkey. In Maternal health and family planning services and induced abortions in Turkey: Advanced analysis of the Turkish Population and Health Survey 1998. 1st edition. Ankara: Hacettepe University, TAP foundation and UNFPA, 2002:151-182
4. Elul B, Hajri S, Ngoc NN, et al. Can women in lessdeveloped countries use a simplified medical abortion regimen? Lancet 2001;357:1402-1405
5. Blum J, Hajri S, Chélli H, et al. The medical abortion experiences of married and unmarried women in Tunis, Tunisia. Contraception 2004;69:63-69
6. AkinA, Blum J,O zalp S, et al. Results and lessons learned from a small medical abortion clinical study in Turkey. Contraception 2004;70:401-406
7. World Health Organization Task Force on Post- Ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307:532-537
8. Ngoc NN, Nhan VQ, Blum J, et al. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. Br J Obstet Gynaecol 2004;111:814-819
9. Clark W, Shannon C, Winikoff B. Misoprostol for uterine evacuation in induced abortion and pregnancy failure. Expert Rev Obstet Gynecol 2007;2:67-108.
10. Bracken H, Gliozheni O, Kati K, et al. Mifepristone medical abortion in Albania: Results from a pilot clinical research study. Eur J Contracept Reprod Health Care 2006;11:38-46.
11. Clark WH, Hassoun D, Gemzell-Danielsson K, et al. Home use of two doses of misoprostol after mifepristone for medical abortion:Apilot study in Sweden and France. Eur J Contracept Reprod Health Care 2005;10:184-189
12. Guengant JP, Bangou J, Elul B. Mifepristone-misoprostol medical abortion: Home administration of misoprostol in Guadeloupe. Contraception 1999;60:167-172
13. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception 2001;64:81-85
14. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mcg for abortion up to 63 days of pregnancy. Contraception 2002;66:247-250
15. Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005;72:328-332
16. Hamoda H, Ashok PW, Dow J, et al. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contraception 2003; 68:335-338
17. Tang OS, Xu J, Cheng L, et al. Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. Hum Reprod 2002;17:1738-1740
18. Tang OS, Chan CC, Ng EH, et al. A prospective, randomized, placebo controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortion of less than 9 weeks gestation. Human Reprod 2003;18:2315-2318
19. Singh KC, Ummat S, Rajaram S, et al. First trimester abortion with mifepristone and three doses of sublingual misoprostol: A pilot study. Aust NZ J Obstet Gynaecol 2005;45:495-498
20. Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Human Reprod 2002;17:332-336
21. Rorbye C, Norgaard M, Vestermark V, et al. Medical abortion: Defining success and categorizing failures. Contraception 2003;68:247-251
22. Rorbye C, Norgaard M, Vestermark V, et al. Prediction of late failure after medical abortion from serial B-hCG measurements and ultrasonography. Hum Reprod 2004; 19:85-89
23. Akýn A., Dogan GB, Dilbaz B, et al. In Medical abortion is a new choice for Turkey. Ankara: Hacettepe University Medical Faculty Public Health Department, 2005.